Limits...
Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries.

Foo J, Landis SH, Maskell J, Oh YM, van der Molen T, Han MK, Mannino DM, Ichinose M, Punekar Y - PLoS ONE (2016)

Bottom Line: Indirect costs were calculated from work loss values using the Work Productivity and Activity Impairment scale.Combined direct and indirect costs estimated the total societal costs per patient.The annual direct costs of COPD ranged from $504 (South Korea) to $9,981 (USA), with inpatient hospitalisations (5 countries) and home oxygen therapy (3 countries) being the key drivers of direct costs.

View Article: PubMed Central - PubMed

Affiliation: Health Outcomes, GlaxoSmithKline, Uxbridge, United Kingdom.

ABSTRACT

Background: The Continuing to Confront COPD International Patient Survey estimated the prevalence and burden of COPD across 12 countries. Using data from this survey we evaluated the economic impact of COPD.

Methods: This cross-sectional, population-based survey questioned 4,343 subjects aged 40 years and older, fulfilling a case definition of COPD based on self-reported physician diagnosis or symptomatology. Direct cost measures were based on exacerbations of COPD (treated and those requiring emergency department visits and/or hospitalisation), contacts with healthcare professionals, and COPD medications. Indirect costs were calculated from work loss values using the Work Productivity and Activity Impairment scale. Combined direct and indirect costs estimated the total societal costs per patient.

Results: The annual direct costs of COPD ranged from $504 (South Korea) to $9,981 (USA), with inpatient hospitalisations (5 countries) and home oxygen therapy (3 countries) being the key drivers of direct costs. The proportion of patients completely prevented from working due to their COPD ranged from 6% (Italy) to 52% (USA and UK) with 8 countries reporting this to be ≥20%. Total societal costs per patient varied widely from $1,721 (Russia) to $30,826 (USA) but a consistent pattern across countries showed greater costs among those with increased burden of COPD (symptoms, health status and more severe disease) and a greater number of comorbidities.

Conclusions: The economic burden of COPD is considerable across countries, and requires targeted resources to optimise COPD management encompassing the control of symptoms, prevention of exacerbations and effective treatment of comorbidities. Strategies to allow COPD patients to remain in work are important for addressing the substantial wider societal costs.

Show MeSH

Related in: MedlinePlus

Annual societal costs per patient using exchange rates of COPD stratified by disease and patient characteristics: Continuing to Confront COPD International Patient Survey, 2012–13.(A) By mMRC grade. (B) By CAT score. (C) By self-perceived severity of COPD. (D) By Comorbidities. Abbreviations: CAT, COPD Assessment Test; mMRC, modified Medical Research Council Scale; USA, United States of America, UK, United Kingdom, NL, Netherlands; SK, South Korea
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4836731&req=5

pone.0152618.g004: Annual societal costs per patient using exchange rates of COPD stratified by disease and patient characteristics: Continuing to Confront COPD International Patient Survey, 2012–13.(A) By mMRC grade. (B) By CAT score. (C) By self-perceived severity of COPD. (D) By Comorbidities. Abbreviations: CAT, COPD Assessment Test; mMRC, modified Medical Research Council Scale; USA, United States of America, UK, United Kingdom, NL, Netherlands; SK, South Korea

Mentions: The total societal costs per patient were greater in patients who reported increased levels of breathlessness (mMRC ≥2), greater impact on health status (CAT score >20), and perceived themselves to have more severe COPD, than in those reporting less symptoms and less severe disease (Fig 4). These findings were consistent across all countries. Patients who reported having two or more comorbidities were slightly more costly than patients with none or one comorbidity, across most countries (an exception was France where costs were similar) (Fig 4).


Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries.

Foo J, Landis SH, Maskell J, Oh YM, van der Molen T, Han MK, Mannino DM, Ichinose M, Punekar Y - PLoS ONE (2016)

Annual societal costs per patient using exchange rates of COPD stratified by disease and patient characteristics: Continuing to Confront COPD International Patient Survey, 2012–13.(A) By mMRC grade. (B) By CAT score. (C) By self-perceived severity of COPD. (D) By Comorbidities. Abbreviations: CAT, COPD Assessment Test; mMRC, modified Medical Research Council Scale; USA, United States of America, UK, United Kingdom, NL, Netherlands; SK, South Korea
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4836731&req=5

pone.0152618.g004: Annual societal costs per patient using exchange rates of COPD stratified by disease and patient characteristics: Continuing to Confront COPD International Patient Survey, 2012–13.(A) By mMRC grade. (B) By CAT score. (C) By self-perceived severity of COPD. (D) By Comorbidities. Abbreviations: CAT, COPD Assessment Test; mMRC, modified Medical Research Council Scale; USA, United States of America, UK, United Kingdom, NL, Netherlands; SK, South Korea
Mentions: The total societal costs per patient were greater in patients who reported increased levels of breathlessness (mMRC ≥2), greater impact on health status (CAT score >20), and perceived themselves to have more severe COPD, than in those reporting less symptoms and less severe disease (Fig 4). These findings were consistent across all countries. Patients who reported having two or more comorbidities were slightly more costly than patients with none or one comorbidity, across most countries (an exception was France where costs were similar) (Fig 4).

Bottom Line: Indirect costs were calculated from work loss values using the Work Productivity and Activity Impairment scale.Combined direct and indirect costs estimated the total societal costs per patient.The annual direct costs of COPD ranged from $504 (South Korea) to $9,981 (USA), with inpatient hospitalisations (5 countries) and home oxygen therapy (3 countries) being the key drivers of direct costs.

View Article: PubMed Central - PubMed

Affiliation: Health Outcomes, GlaxoSmithKline, Uxbridge, United Kingdom.

ABSTRACT

Background: The Continuing to Confront COPD International Patient Survey estimated the prevalence and burden of COPD across 12 countries. Using data from this survey we evaluated the economic impact of COPD.

Methods: This cross-sectional, population-based survey questioned 4,343 subjects aged 40 years and older, fulfilling a case definition of COPD based on self-reported physician diagnosis or symptomatology. Direct cost measures were based on exacerbations of COPD (treated and those requiring emergency department visits and/or hospitalisation), contacts with healthcare professionals, and COPD medications. Indirect costs were calculated from work loss values using the Work Productivity and Activity Impairment scale. Combined direct and indirect costs estimated the total societal costs per patient.

Results: The annual direct costs of COPD ranged from $504 (South Korea) to $9,981 (USA), with inpatient hospitalisations (5 countries) and home oxygen therapy (3 countries) being the key drivers of direct costs. The proportion of patients completely prevented from working due to their COPD ranged from 6% (Italy) to 52% (USA and UK) with 8 countries reporting this to be ≥20%. Total societal costs per patient varied widely from $1,721 (Russia) to $30,826 (USA) but a consistent pattern across countries showed greater costs among those with increased burden of COPD (symptoms, health status and more severe disease) and a greater number of comorbidities.

Conclusions: The economic burden of COPD is considerable across countries, and requires targeted resources to optimise COPD management encompassing the control of symptoms, prevention of exacerbations and effective treatment of comorbidities. Strategies to allow COPD patients to remain in work are important for addressing the substantial wider societal costs.

Show MeSH
Related in: MedlinePlus